Clinically, high CCL2 expression was associated with a decreased overall survival rate in BC patients [60], and high endocrine CCL2 increased the aggressiveness of human inflammatory BC and led to a poor prognosis [63]. The gene discussed is CCL2; the disease is breast cancer.